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Abstract
Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in
previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD
patients. The objective of this study was to evaluate impact of switching originator to biosimilar IFX on HRQoL, disease activity, and
health care costs in IBD maintenance treatment.
In this single-center prospective observational study, all IBD patients receiving maintenance IFX therapy were switched to
biosimilar IFX. HRQoL was measured using the generic 15D health-related quality of life instrument (15D) utility measurement and the
disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ). Crohn Disease Activity Index (CDAI) or Partial Mayo Score
(pMayo), and fecal calprotectin (FC) served for evaluation of disease activity. Data were collected at time of switching and 3 and 12
months after switching. Patients’ characteristics, clinical background information and costs were collected from patient records and
the hospital’s electronic database.
Fifty-four patients were included in the analysis. No statistically significant changes were observed in 15D, CDAI, pMayo, and FC
during 1-year follow-up. IBDQ scores were higher (P= .018) in Crohn disease 3 months after switching than at time of switching.
Costs of biosimilar IFX were one-third of costs of originator one. Total costs related to secondary health care (excluding costs of IFX),
were similar before and after the onset of biosimilar IFX.
HRQoL and disease activity were after switching from originator to biosimilar IFX comparable, but the costs of biosimilar IFX were
only one-third of those of the originator one.
Abbreviations: 15D = 15D health-related quality of life instrument, CD = Crohn disease, CDAI = Crohn Disease Activity Index,
EMA = European Medicines Agency, FC = fecal calprotectin, HRQoL = health-related quality of life, HUS = Helsinki University
Hospital, IBD = inflammatory bowel disease, IBDQ = Inflammatory Bowel Disease Questionnaire, IBD-u = inflammatory bowel
disease unclassified, IFX = infliximab, IQR = interquartile range, pMayo = partial mayo score, SD = standard deviation, UC =
ulcerative colitis.
Keywords: biosimilar, Crohn disease, health-related quality of life, inflammatory bowel disease, infliximab, ulcerative colitis
1. Introduction
Inflammatory bowel diseases (IBD), including Crohn disease
(CD), ulcerative colitis (UC), and IBD unclassified (IBD-u),
are conditions characterized by chronic inflammation of the
gastrointestinal tract. The worldwide incidence of IBD has
increased since the latter part of 20th century affecting mainly
young adults and causing an increasing economic burden.[1,2]
During the last two decades, the use of the biological drugs has
increased significantly. Biologics have been shown to be effective
in inducing and maintaining remission in IBD.[3,4] However, they
are significantly more expensive than conventional drugs.
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Therefore, interest has grown in biosimilars that are comparable
to the originator product in terms of efficacy and safety. In June
2013, the biosimilar infliximab (IFX), CT-P13, was accepted by
the European Medicines Agency (EMA) for all indications of the
originator product.[5] Studies demonstrating efficacy of bio-
similar IFX were conducted in ankylosing spondylitis and
rheumatoid arthritis, and these results were extrapolated for
IBD, causing concern in IBD societies.[6–8] The effectiveness,
efficacy and safety of biosimilar IFX in IBD patients has been
shown in previous studies.[9–15] The objective of this study was to
evaluate HRQoL, disease activity, and health care costs before
and after switching originator to biosimilar IFX in the
maintenance treatment of Finnish IBD patients.
2. Methods
2.1. Study design
In this investigator-initiated, prospective, observational, single-
center study, all adult IBD patients (≥18 years) receiving
maintenance IFX (RemicadeTM, Janssen Biotech, Inc/ Schering-
Plough, EU) treatment at Helsinki University Hospital were
switched to biosimilar IFX (RemsimaTM, Celltrion Pharm, Inc.,
South Korea) in the beginning of 2016. Before the administration
of the first biosimilar IFX in the day care unit, all IBD patients
with IFX treatment were asked to participate in the study (Fig. 1).
Whether patients chose to participate in the study or not, all adult
IBD patients (≥18 years) receiving maintenance IFX therapy were
switched to a biosimilar one, and they received all the services
they usually did. At the time of administration of the first
biosimilar IFX, IBD patients were asked to complete a
questionnaire concerning HRQoL and disease activity. Patients
who had returned the first questionnaire and the informed
consent form were asked to answer follow-up questionnaires at 3
and 12months after switching. One reminder was sent to patients
who had not returned the follow-up questionnaires.
The generic HRQoL measure used in this study was 15D
health-related quality of life instrument (15D), which is 15-
dimensional, standardized, and self-administered instrument that
can be used both as a profile and as a single index score measure
covering the most important dimensions of health including
mobility, vision, hearing, breathing, sleeping, eating, speech
(communication), excretion, usual activities, mental function,
discomfort and symptoms, depression, distress, vitality, and
sexual activity.[16,17] Each dimension is divided into five levels
from no problems to extreme problems. The single-index 15D
score, representing the overall HRQoL on a scale of 0–1 (0=
being dead, 1=no problems on any dimensions) calculated from
the health state descriptive system by using a set of population-
based preference or utility weights. A change of approximately
±0.015 in the total 15D score is considered clinically or
practically important because people can usually sense such a
magnitude of change.[18] If patient did not answer all the
Figure 1. Flowchart of the patients included in the study. CD=Crohn disease, IBD= inflammatory bowel disease, IFX= infliximab, UC=ulcerative colitis.
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questions of the 15D, one to three missing responses were
predicted with linear regression analysis using other dimensions,
age, and sex as independent variables.[19]
Disease-specific HRQoL information was collected with the
IBDQ. The IBDQ is a widely used, standardized measure for
assessment of HRQoL in patients with IBD. The IBDQ includes
32 items, which are divided into four subscales: gastrointestinal
symptoms (10 items), systemic symptoms (5 items), emotional
function (12 items) and social function (5 items) and each item is
scored on a 7-point scale, ranging from 1 to 7 (worst to best of
health).[20] The total IBDQ scores may range from 32 to 224,
with higher scores representing better health. The scores of
patients in clinical remission usually are 170 points or more.[21] A
clinically meaningful improvement is an increase ≥16 points in
the total IBDQ score in CD, and a mean decrease in relapse is
about 32 points.[21,22] One unanswered item of IBDQ subscale
was replaced by the mean of the items of the respective subscale.
The IBDQ questionnaire was excluded from further analyses if
more than one item of subscale was missing. The IBDQ was used
under license from McMaster University, Hamilton, Canada.
Clinical disease activity assessment in CDwas based on the CD
Activity Index (CDAI).[23] CDAI less than 150 indicates
remission, and scores 150 to 219 mildly, 220 to 450 moderately,
and >450 severely active disease. In UC and IBD-u, clinical
disease activity assessment was based on the partial Mayo Score
(pMayo). The numerical results provide a score ranging from 0 to
9 that represents an estimate of clinical activity of UC, and clinical
remission was defined as pMayo<2.[24] Fecal calprotectin (FC)
served for objective measurement of disease activity and was
measured by a quantitative enzyme immunoassay (PhiCal Test,
Calpro AS, Oslo, Norway). The FC values quoted as normal were
<100mg/g of stool.[25] The patients’ clinical background
information regarding the disease state and the treatments given
were collected from the hospital records.
The study was conducted from the healthcare provider
perspective. The costs of production of the services were obtained
from the hospital accounting records of the Helsinki University
Hospital (HUS), where all costs of specialized health care of
individual patients were stored on a routine basis.[26–29] The total
cost data covered all costs related to the secondary health care
provider (intervention, ward, ambulatory visits, laboratory,
radiology, pathology, outpatient visits). Regardless of the
diagnosis, all costs of specialized health care of IBD patients
were analyzed. No productivity costs or outpatient drug costs
were included. Costs of IFXwere calculated based on the hospital
records. Discounting was not considered in the study as the data
were based only on years 2015 and 2016. All costs were
converted to 2017 euros using the health care price index of
Statistics Finland.[30] The primary outcomes of the study were
the changes in HRQoL, disease activity, and costs during the
follow-up up.
2.2. Statistical analyses
The statistical significance of the difference in mean 15D scores
during follow-up was tested with paired samples t test. As the
15D variables were not normally distributed and the patient size
was relatively small, the Wilcoxon Signed Rank test as non-
parametric test was also applied. Aside from minor differences in
the level of statistical significance, the results of parametric and
non-parametric tests were similar. Therefore, only results of
parametric tests are reported for the 15D. The Wilcoxon Signed
Rank test was used to test the statistical significance between
variables in IBDQ, CDAI, pMayo, FC, health service use and
costs during the follow-up. The Mann-Whitney U Test was used
to examine differences between patients included and excluded
from the study. The results are given as mean and standard
deviation (SD) or as median and interquartile range (IQR).
Values less than 0.05 were considered statistically significant.
Statistical analyses were performed for CD and UC patients, and
patients with IBD-u were included in the UC group. Subgroup
analyses were conducted for patients in remission at the time of
switching. The data were analyzed using IBM SPSS Statistics 24
(SPSS, Inc.).
2.3. Ethical considerations
Ethical approval was granted by the Ethics Committee of
Medicine of HUS (32/13/03/01/2016). The research permit was
given by the HUS (HUS-170-2016-2 andHUS-333-2019-23). All
participants signed informed consent form.
3. Results
3.1. Patients
Of the 252 eligible IBD patients, 75were willing to participate and
returned their informed consent and questionnaire at the time of
switching (Fig. 1). A total of 21 patients were excluded from the
study, and, consequently, 54 patients were included in the final
analysis. Of these 54 patients, 48 (88.9%) and 43 (79.6%) replied
to the questionnaire at 3 and 12 months after the switching. The
characteristics of the patients included in the study are presented in
the Table 1. Patient characteristics were similar between patients
included (n=54) and excluded (n=21) from the final analysis,
except in the duration of IFX treatment (P= .017) and the location
ofCDaccording to theMontreal classification (P= .007) inCD.Of
the patients who discontinued the IFX treatment (n=3), 1 patient
switched to another biologic treatment, 1 patient achieved
remission, and one patient discontinued IFX treatment based on
IFX trough levels. Two patients, who were lost to follow-up, had
moved out of the hospital district.
3.2. Health-related quality of life
At the time of switching and at 3 and 12 months after it, the 15D
scores in the whole study group ranged from 0.745 to 1, from
0.687 to 1, and from 0.700 to 1, respectively. At the same points
of measurement, full health (the 15D score=1) was reported by
12%, 20%, and 15% of CD patients, respectively, and by 7%,
7%, and 17% of UC patients, respectively. Compared to the time
of switching, the mean 15D scores in CD (P= .310 and P= .129)
and in UC patients (P= .470 and P= .319) did not differ at 3 and
12 months, respectively (Table 2). A clinically important
difference was not observed in UC, whereas in CD patients
the change in the total 15D scores between 3 and 12 months was
clinically important. The proportion of patients that experienced
at least a minimum clinically important change in HRQoL 12
months after the switching was 40% for improvement and 31%
for deterioration in the whole study group (Table 3). Regarding
the different dimensions, statistically significant difference was
observed in excretion (P= .042) and in breathing (P= .021) in CD
as compared to the time of switching, whereas in UC no
statistically significant differences (all P> .05) on any dimension
were not observed (Figs. 2 and 3).
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Table 1
Patient characteristics at the time of switching.
CD (n=26) UC/IBD-u (n=28)
Gender: male, n (%) 18 (69.2) 12 (42.9)
Age, years, median (IQR) 36 (28–48) 35 (27.5 – 39)
Duration of disease, years, median (IQR) 13 (9–25) 8 (5–13.8)
Duration of infliximab use, years, median (IQR) 4.0 (1.6 – 7.8) 2.0 (0.7 – 3.0)
Montreal classification, n (%)
A1, A2, A3 6 (21.1), 18 (69.2), 2 (7.7) –
L1, L2, L3, L4 1 (3.8), 6 (23.1), 19 (73.1), 4 (15.4) –
B1, B2, B3 13 (50.0), 7 (26.9), 6 (23.1) –
Perianal disease 6 (23.1) –
E2, E3 8 (28.6), 20 (71.4)
Smoking, n (%)
No 13 (52.0) 15 (53.6)
Yes 9 (36.0) 2 (7.1)
Former 3 (12.0) 11 (39.3)
Former surgical treatment, n (%)
Yes 13 (50.0) 1 (3.6)
No 13 (50.0) 27 (96.4)
Concomitant medication, n (%)
Azathioprine 15 (57.7) 14 (50.0)
6-Mercaptopurin – 2 (7.1)
Methotrexate 2 (7.7) 3 (10.7)
Mesalamine 2 (7.7) 14 (50.0)
Corticosteroids 1 (3.8) 3 (10.7)
CD=Crohn disease, IBD-u= inflammatory bowel disease unclassified, IQR= interquartile range, UC=ulcerative colitis.
Table 2







P value between the
time of switching
and 3 mo later
P value between the
time of switching and
12 mo later
CD patients
n 26 20 20
The 15D score, mean (SD)
∗
0.915 (0.073) 0.928 (0.077) 0.901 (0.089) .310 .129
IBDQ score, median (IQR)† 188 (170–198) 193 (190–206) 190 (163–204) .018 .751
CDAI score, median (IQR)† 67.45 (30.46–91.39) 52.00 (17.79–96.00) 78.07 (11.00–152.03) .227 .756
Calprotectin mg/g, median (IQR)† 100 (25–338) 152 (42–295) 129 (31–329) .583 .586
UC/IBD-u patients
n 28 28 23
The 15D score, mean (SD)
∗
0.908 (0.070) 0.903 (0.088) 0.906 (0.0780) .483 .333
IBDQ score, median (IQR)† 181 (146–199) 190 (150–207) 193 (162–202) .094 .726
Partial Mayo score, median (IQR)† 1.00 (1.00–2.00) 1.00 (1.00–3.00) 1.00 (1.00–3.00) .971 .829
Calprotectin mg/g, median (IQR)† 32 (10–325) 71 (2–402) 22 (5–66) .715 .149
CD=Crohn disease, IBD-u= inflammatory bowel disease unclassified, IQR= interquartile range, SD= standard deviation, UC=ulcerative colitis.
∗
Paired samples t test was used to test statistical significance.
†Wilcoxon Signed Rank test was used to test statistical significance.
Table 3
Classification of the changes in 15D scores from the time of switching to 3 and 12months into global assessment scale categories and the
distribution of the patients into these categories.
Patients from time of switching
to 3 mo after switching, n (%)
Patients from time of switching
to 12 mo after switching, n (%)
Global assessment category Limits for change in 15D score
∗
CD patients UC/IBD-u patients CD patients UC/IBD-u patients
Much better >0.035 7 (35.0) 3 (10.7) 3 (15.0) 4 (17.4)
Slightly better 0.015 to 0.035 2 (10.0) 5 (16.1) 2 (10.0) 4 (17.4)
Much the same (no change) >–0.015 and <0.015 5 (25.0) 12 (38.7) 2 (10.0) 5 (21.7)
Slightly worse –0.015 to –0.035 3 (15.0) 3 (9.7) 6 (30.0) 4 (17.4)
Much worse <–0.035 3 (15.0) 5 (16.1) 7 (35.0) 6 (26.1)
∗
For the limits, see Alanne et al.[18]
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At the time of switching and 3 and 12months later, IBDQ score
≥170 (considered remission) was reported by 73%, 85%, and
70%of CD patients, respectively, and by 64%, 69%, and 70%of
UC patients, respectively. Statistically significant improvement
(P= .018) was observed in IBDQ scores at 3 months after
switching in CD (Table 2). Compared to the time of switching,
statistically significant difference was observed neither in CD
(P= .088 and P= .932) nor in UC patients (P= .117 and .586) at 3
and 12 months, respectively, when patients in remission at the
time of switching were only considered. The percentages of
Figure 2. The 15D profile in Crohn disease patients.
∗
statistically significant difference (P< .05) from the time of switching to 3 months after switching.
∗∗
statistically
significant difference (P< .05) from the time of switching to 12 months after switching. Paired samples t test was used to test statistical significance.
Figure 3. The 15D profile in ulcerative colitis and inflammatory bowel disease unclassified patients. Paired samples t test was used to test statistical significance.
IBD-u= IBD-unclassified, UC=ulcerative colitis.
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patients who met an IBDQ change ≥16 (considered clinically
meaningful improvement) was 5% (n=1) in CD and 17% (n=4)
in UC 12months after switching. The total IBDQ score decreased
by more than 32 points (considered relapse) in one UC patient 12
months after switching.
3.3. Disease activity
At the time of switching and at 3 and 12months later, a CDAI less
than 150 (considered remission) was reported by 92%, 89%, and
63%of CDpatients, respectively. pMayo score of<2 (considered
remission) was reported by 63%, 63%, and 76% of UC patients,
respectively. At respective points of measurement, median FC
concentration was 82 (IQR 13–312), 83 (IQR 26–300), and 33
(IQR 10–186) in the whole study group. Compared to the time of
switching, changes in the CDAI (P= .227 and P= .756), pMayo
(P= .971 and P= .829), or FC concentration (CD: P= .583 and
.586; UC: P= .715 and .149) showed no difference at 3 and 12
months, respectively (Table 2). When patients in remission at the
time of switching were only considered, changes in the CDAI
(P= .227 and P= .826) and pMayo (P= .317 and P= .157) were
not significantly different at respective time points.
3.4. Health service use and costs
The number of IFX administration visits and IFX doses between
2015 (IFX originator used) and 2016 (IFX biosimilar used)
showed neither in CD (P= .590 and P= .109) nor in UC (P= .372
and .225) a statistically significant difference (Table 4). Costs of
IFX were significantly higher (P< .001) in 2015 than in 2016.
Costs of IFX in 2016 were 35% of costs of IFX in 2015. The
mean total costs covering all costs related to the secondary health
care provider (intervention, ward, ambulatory visits, laboratory,
radiology, pathology, outpatient visits, and excluding the costs
of IFX) were 4405 € (SD 4132) per patient in the whole study
group in 2015, while costs were 3830 € (SD 2573) in 2016.
When patients who started IFX treatment in 2015 (4 CD
patients and 10UC/IBD-u patients) were excluded, the mean
total costs were 3804€ (SD 3771) per patient in 2015 and 3886
€ (SD 2597) per patient in 2016. Total costs related to secondary
health care (excluding the costs of IFX) between 2016 and 2015
showed neither in the whole study group (P= .799) nor in
patients who had started IFX treatment before 2015 a difference
(P= .340).
4. Discussion
The aim of this single-center observational study was to evaluate
HRQoL, disease activity, and costs of switching originator to
biosimilar one in the maintenance treatment of Finnish IBD
patients. Based on this study, HRQoL measured by the generic
15D of biosimilar IFX was comparable to that during originator
one in the 1-year study follow-up. Statistically significant
improvement was observed in IBDQ scores between the time
of switching and 3 months in CD. However, statistically
significant difference was not observed when CD patients in
remission at the time of switching were only considered. There
were no changes in clinical or FC-measured disease activity after
switching. The costs of biosimilar IFX were around one-third of
the costs of originator one, whereas costs related to secondary
health care (excluding the costs of IFX) were similar in 2015
(originator IFX used) and 2016 (biosimilar IFX used).
Consistent with our results, previous studies showed compa-
rable disease activity between originator IFX and biosimilar
one.[9–14] Different from the previous studies, our study showed
statistically significant improvement in IBDQ scores 3 months
after the switching in CD as compared with the time of switching.
However, a statistically significant difference was not anymore
present at 12 months after the switching. Furthermore, the
generic HRQoL measure, the 15D suggest that IFX biosimilar is
comparable to originator one, and therefore, results of IBDQ
should be interpreted with caution. It is unclear whether the
change in IBDQ scores is due to the switching to IFX biosimilar or
due to other patients’ characteristics or clinical background
information.
The strength of this study is its prospective nature and that all
adult IBD patients (≥18 years) receiving maintenance IFX
therapy were systemically switched to biosimilar one whether
they participated in the study or not. It is also notable, that study
population consisted of IBD patients treated in a tertiary clinic,
representing IBD patients most difficult to treat. Another strength
of this studywas its relatively long follow-up as bothHRQoL and
disease activity were measured at the time of switching and at 3
and 12 months later. Furthermore, both clinical and objective
Table 4
Infliximab doses and costs per patient in a specialized health care.
2015 2016 P value
CD patients (n=26)
Number of IFX doses per year, median (IQR) 7 (6–7) 7 (6–7) .590
IFX dose, mg, median (IQR) 400 (300–500) 400 (300–500) .109
Cost of IFX per dose, €, median (IQR) 1700 (1270–2126) 595 (446–743) .000
Cost of IFX per year, €, median (IQR) 11,784 (9001–15,397) 4162 (3122–5277) .000
Total costs related to the secondary healthcare provider per year
∗
, €, median (IQR) 3202 (2297–5081) 3898 (2284–5608) .909
UC/IBD-u patients (n=28)
Number of IFX doses per year, median (IQR) 6 (5–8) 7 (6–8) .372
IFX dose, mg, median (IQR) 300 (300–400) 300 (300–400) .225
Cost of IFX per dose, €, median (IQR) 1276 (1268–1703) 476 (446–650) .000
Cost of IFX per year, €, median (IQR) 8978 (7689–11,908) 3568 (2750–4460) .000
Total costs related to the secondary healthcare provider per year
∗
, €, median (IQR) 2648 (2234–3837) 2763 (2068–3687) .666
Wilcoxon Signed Rank test was used to test statistical significance.
CD=Crohn disease, IBD-u= inflammatory bowel disease unclassified, IFX= infliximab, UC=ulcerative colitis.
∗
Excluding costs of IFX.
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disease specific measures were used to evaluate disease activity. In
this study, the mean 15D and IBDQ scores of IBD patients during
1-year follow-up were 0.901 to 0.928 and 175.93 to 190.94,
respectively. These scores are higher than the mean 15D score of
0.874 and the mean IBDQ score of 163 in Finnish IBD patients
reported by Haapamäki et al.[31] Additionally, the mean 15D
score was 0.868 for the Finnish IBD patients of the Health 2000
survey.[32] Based on the NOR-SWITCH study, the mean IBDQ
score in IBD was 187 to 190, which is comparable to the mean
IBDQ score of this study.[12] The 15D score has shown to be
strongly related to the total IBDQ score and disease activity.[31]
According to the study by Haapamäki et al, the total 15D scores
of IBD patients in clinical remission can be estimated to be about
0.89 or higher.[31] In this study, the 15D score of 0.89 or higher
was observed by 65%, 75%, and 60% of CD patients and by
57%, 68%, and 65% of UC patients at time of switching and 3
and 12 months later, respectively. This finding is in line with
IBDQ, CDAI, and pMayo, as most IBD patients in this studywere
in remission.
This study showed that costs of biosimilar IFX were
significantly lower than costs of originator one. The costs of
production of the services (excluding the costs of IFX) were
obtained from the hospital accounting records by HUS,[26–29]
where all costs of specialized health care of individual patients
were analyzed regardless of the diagnosis. Therefore, costs of
specialized health care were not IBD-related, but this study
showed that IFX biosimilar had no impact on the costs related
to specialized health care (excluding the costs of IFX).
Adalimumab has also reached, and many other biologic drugs
are approaching, patent expiry. Biosimilar drugs offer consid-
erable cost reductions in health care, and in turn, biologic
treatment may become available for a larger number of IBD
patients.
Among the limitations of our study is a lack of a control
group continuing originator IFX. Another limitation is a
relatively small patient number. Although patient character-
istics were similar between patients included (n=54) and
excluded (n=21) from the final analysis, except for CD patients
in the duration of IFX treatment (P= .017) and the location of
CD according to the Montreal classification (P= .007), a
weakness of this study is the unknown difference between non-
participants (n=177) and participants (n=75). Those who did
not take part in the study may have been unaware of their
symptoms and their impact on HRQoL. It is also notable that
patients were aware of the fact that they switched to biosimilar
IFX which may have influenced the results. No productivity
costs or outpatient drug costs were analyzed in this study. The
status of working and number of sickness leave days were
asked in the questionnaire but not analyzed in the study due to
defective data.
In conclusion, this study suggested that in maintenance therapy
of IBD biosimilar IFX was, in light of the 15D, CDAI, pMayo,
and FC, comparable to originator one during 1-year study
follow-up. The costs of biosimilar IFX were around one-third of
the costs of originator one, whereas costs related to secondary
health care were similar before and after the onset of biosimilar
IFX.
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